MOUNJARO 2.5mg (Tirzepatide PFS) 2.5mgx0.5ml

Tirzepatide, the active ingredient in Mounjaro, activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, thereby helping to regulate blood sugar levels in patients with type 2 diabetes mellitus.

The usual starting dose of Mounjaro is 2.5 mg once weekly. The dose can be increased gradually based on the patient's glycemic control and tolerability, as determined by the prescribing healthcare provider. The maximum recommended dose is 15 mg once weekly for adults and 10 mg once weekly for pediatric patients.

The safety of Mounjaro during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider to discuss the potential risks and benefits before using Mounjaro in these situations. Pregnancy should be avoided during treatment with Mounjaro unless clearly necessary.

To order Mounjaro from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping, and the import paperwork.

Mounjaro is a dual GIP/GLP-1 receptor agonist, which distinguishes it from other diabetes medications that may target only one of these receptors or use different mechanisms. Its dual action can provide more comprehensive glycemic control and may offer additional benefits such as weight loss, though it is not approved specifically for weight management.

Mounjaro should be stored at 2-8°C, refrigerated, and protected from light. It should not be frozen or shaken. Always follow the storage instructions provided with the medication to ensure its efficacy and safety.

Mounjaro is administered as a subcutaneous injection once weekly. The pre-filled single-dose pen makes it convenient for self-administration or administration by a healthcare provider. It is important to follow the administration instructions provided with the medication.

The most serious risks to watch for with Mounjaro include symptoms of pancreatitis (severe abdominal pain), hypoglycemia (low blood sugar), kidney problems (dehydration), allergic reactions (swelling, difficulty breathing), and thyroid tumors (lump or swelling in the neck, hoarseness). Patients should report any of these symptoms to their healthcare provider immediately.

Mounjaro should not be used by patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also contraindicated in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Always consult with a healthcare provider to determine if Mounjaro is appropriate for you.